- |||||||||| lanerkitug (BAY 3375968) / Bayer
Enrollment change, Monotherapy, Metastases: A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 20, 2024
P1, N=354, Recruiting,
N=270 --> 354
- |||||||||| lanerkitug (BAY 3375968) / Bayer
Enrollment open, Monotherapy, Metastases: A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 14, 2022
P1, N=270, Recruiting,
BAY 3375968 is currently under investigation in a Phase I clinical trial (NCT05537740). Not yet recruiting --> Recruiting
- |||||||||| lanerkitug (BAY 3375968) / Bayer
New P1 trial, Monotherapy, Metastases: A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 13, 2022
P1, N=270, Not yet recruiting,
|
